𝔖 Bobbio Scriptorium
✦   LIBER   ✦

RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain

✍ Scribed by Berta Campos; Orland Díez; Montserrat Domènech; Manel Baena; Judith Balmaña; Judit Sanz; Amaya Ramírez; Carmen Alonso; Montserrat Baiget

Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
122 KB
Volume
22
Category
Article
ISSN
1059-7794

No coin nor oath required. For personal study only.

✦ Synopsis

Germ-line mutations in the breast cancer susceptibility genes BRCA1 and BRCA2 account for a large proportion of hereditary breast/ovarian cancer families. A large number of disease-causing germ-line mutations and variants of unknown pathological significance have been identified in both genes. The majority of these variants have been studied only in genomic DNA and their effects at the mRNA level have not been reported. Our aim was to ascertain the pathological effect of six BRCA1 and two BRCA2 sequence unclassified variants by RNA analysis. Three of the BRCA1 variants are novel: IVS18+5G>A, IVS20-6_IVS20-4del and IVS22-2A>G. Three BRCA1 mutations showed aberrant splicing: Ala1693del, IVS18+5G>A and IVS22-2A>G. The variants G1706A, S1715N and IVS20-6_IVS20-4del in BRCA1, and T2515I and IVS25+9A>C in BRCA2 led to normal transcripts. We compared these RNA results with those obtained from two theoretical splicing prediction methods. The consensus values for the splice sequences (Shapiro and Senapathy 1987) involved in three of the BRCA1 splicing site variants agreed with the RNA results, lending support to the validity of this model. Moreover, we used previously established exonic splicing enhancer (ESE) sequences to ascertain whether the four exonic variants studied fell within predicted ESE motifs and whether they would disrupt ESE functions. Our results suggest that the splicing predictions based o n this method are not definitive and should be considered with caution. This work highlights the importance of studying mutations at DNA and RNA levels in order to clarify their pathological effect. This information is essential for providing efficient counseling for breast/ovarian cancer families.

📜 SIMILAR VOLUMES

BRCA1 and BRCA2 mutation analysis in bre
BRCA1 and BRCA2 mutation analysis in breast-ovarian cancer families from northeastern Poland
✍ Magdalena Perkowska; Izabela BroŻek; Barbara Wysocka; Karin Haraldsson; Therese 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB 👁 1 views

Sixty high-risk breast and/or ovarian cancer families from North-Eastern Poland were screened for germline mutations in BRCA1 (MIM# 113705) and BRCA2 (MIM# 600185), using a combination of protein truncation test, denaturing high-performance liquid chromatography and direct sequencing. Sixteen (27%)

Haplotype analysis of the BRCA2 9254delA
Haplotype analysis of the BRCA2 9254delATCAT recurrent mutation in breast/ovarian cancer families from Spain
✍ Berta Campos; Orland Díez; Fabrice Odefrey; Montserrat Domènech; Virginie Moncou 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB

A frame-shift 9254del5 mutation was independently identified in 12 families, eleven of them with Spanish ancestors, in a BRCA2 screening performed in 841 breast and/or ovarian cancer families and in 339 women with breast cancer diagnosed before the age of 40 at different centers in France and Spain.

Germline mutations of BRCA1 and BRCA2 in
Germline mutations of BRCA1 and BRCA2 in Korean breast and/or ovarian cancer families
✍ Hio Chung Kang; Il-Jin Kim; Jae-Hyun Park; Hyuk-Jun Kwon; Yong-Jin Won; Seung Ch 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 1 views

Germline mutations in the BRCA1 and BRCA2 genes are responsible for the predisposition and development of familial breast and/or ovarian cancer. Most mutations of BRCA1 and BRCA2 associated with breast and/or ovarian cancer result in truncated proteins. To investigate the presence of BRCA1 and BRCA2

Survival of breast cancer patients in BR
Survival of breast cancer patients in BRCA1, BRCA2, and non-BRCA1/2 breast cancer families: A relative survival analysis from Finland
✍ Hannaleena Eerola; Pia Vahteristo; Laura Sarantaus; Pentti Kyyrönen; Seppo Pyrhö 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 69 KB

Reports on the prognosis of familial breast cancer patients have been contradictory. True differences in survival, if they exist, would have important implications for genetic counselling and in treatment of hereditary breast cancer. We assessed the survival rates of 359 familial breast cancer patie

Novel germline BRCA1 and BRCA2 mutations
Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic
✍ Eva Machackova; Jiri Damborsky; Dalibor Valik; Lenka Foretova 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## Communicated by Mark H. Paalman Germline mutations in breast cancer susceptibility genes, BRCA1 and BRCA2, are responsible for a substantial proportion of high-risk breast and breast/ovarian cancer families. To characterize the spectrum of BRCA1 and BRCA2 mutations, we screened Czech families w

Analysis of breast cancer susceptibility
Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer
✍ Pimpicha Patmasiriwat; Kris Bhothisuwan; Olga M. Sinilnikova; Sandrine Chopin; S 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB 👁 1 views

Here we report the study on BRCA1 and BRCA2 mutations in 12 Thai breast and/or ovarian cancer families and 6 early-onset breast or breast/ovarian cancer cases without a family history of cancer. Five distinct rare alterations were identified in each gene: four introducing premature stop codons, one